Clinical trial
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus…
NCT00253201 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00253201 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease |
| Official title | Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Dementia |
| Intervention type | Drug |
| Interventions | galantamine hydrobromide |
| Enrollment | 636 |
| Completion | Oct 1, 1997 |
| First posted | Nov 15, 2005 |
| Last update posted | May 18, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: